BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3216482)

  • 1. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(2):165-70. PubMed ID: 2752714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
    Canawati HN
    Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.
    Reller LB
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):55S-61S. PubMed ID: 6086219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
    Canawati HN
    Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides.
    Aldridge KE; Sanders CV; Marier RL
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):47S-53S. PubMed ID: 6086218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
    Cornick NA; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antibacterial interaction of cefotaxime and desacetylcefotaxime.
    Molinari G; Saverino D; Paglia P; Debbia EA; Schito GC
    J Chemother; 1991 Feb; 3(1):6-12. PubMed ID: 2019866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.
    Jenkins SG
    Diagn Microbiol Infect Dis; 1989; 12(1):51-5. PubMed ID: 2714073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of cefotaxime and ceftizoxime and the role of desacetylcefotaxime in the antibacterial activity of cefotaxime.
    Quintiliani R; Nightingale CH; Tilton R
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):63S-70S. PubMed ID: 6086220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.
    Stevens DL; Bergstrom R; Gibbons A
    Diagn Microbiol Infect Dis; 1989; 12(1):73-80. PubMed ID: 2653715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime.
    Neu HC
    Rev Infect Dis; 1982; 4 Suppl():S374-8. PubMed ID: 6294786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):21S-31S. PubMed ID: 6086215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population analysis of susceptibility to cefotaxime and desacetyl-cefotaxime in Staphylococcus and Enterobacteriaceae.
    Hansen BG; Søgaard P
    Acta Pathol Microbiol Immunol Scand B; 1985 Jun; 93(3):243-7. PubMed ID: 3875967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vitro study of the interaction between cefotaxime and desacetylcefotaxime.
    Winstanley TG; Spencer RC
    Drugs Exp Clin Res; 1986; 12(12):967-71. PubMed ID: 3471432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination.
    Nanetti A; La Placa M
    J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.
    Oizumi K; Hayashi I; Aonuma S; Konno K
    Drugs; 1988; 35 Suppl 2():57-61. PubMed ID: 3135170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.